文献速递肝病

强化生活方式干预对肝硬化合并肥胖患者门静脉高压的影响:SportDiet研究

Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study.
PubMed 文献 · Hepatology · 2017-03-06

这项前瞻性、多中心、非对照试点研究纳入60例代偿期肝硬化合并门静脉高压(HVPG≥6 mm Hg)且BMI≥26 kg/m²的患者,实施16周强化生活方式干预(个体化低热量正常蛋白饮食及每周60分钟监督下体育活动)。干预后体重平均下降5.0±4.0 kg(P<0.0001),HVPG从13.9±5.6降至12.3±5.2 mm Hg(P<0.0001),未发生临床失代偿,16周减重效果维持至6个月。

要点

  • 16周饮食与适度运动在超重/肥胖肝硬化合并门静脉高压患者中安全,减轻体重并降低门静脉压力。
  • 体重下降≥10%者HVPG降幅大于体重下降不足10%者(-23.7±19.9% vs -8.2±16.6%,P=0.024)。

核心结论

  • 16周饮食与适度运动在超重/肥胖肝硬化合并门静脉高压患者中安全,并降低体重和门静脉压力。

研究设计与样本

  • 前瞻性、多中心、非对照试点研究,纳入代偿期肝硬化、HVPG≥6 mm Hg且BMI≥26 kg/m²的患者,实施16周强化生活方式干预(个体化低热量正常蛋白饮食及每周60分钟监督下体育活动)。
  • 共纳入60例患者,50例完成研究(年龄56±8岁;男性62%;非酒精性脂肪性肝炎病因24%;BMI 33.3±3.2 kg/m²;Child A级92%;HVPG≥10 mm Hg者72%)。
  • 干预前后测量HVPG、体重与体成分、脂肪因子、健康相关生活质量及安全性数据;HVPG变化≥10%和体重变化≥5%预设为临床相关;6个月后复评安全性和体重。

主要发现

  • 生活方式干预显著降低体重(平均-5.0±4.0 kg;P<0.0001),52%的患者体重下降≥5%,16%下降≥10%。
  • HVPG显著下降(从13.9±5.6降至12.3±5.2 mm Hg;P<0.0001),42%的患者HVPG下降≥10%,24%下降≥20%。
  • 体重下降≥10%与HVPG更大降幅相关(-23.7±19.9% vs -8.2±16.6%;P=0.024)。
  • 未发生临床失代偿事件;16周时达到的体重下降在6个月时维持;Child和终末期肝病模型评分无变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Obesity increases the risk of clinical decompensation in cirrhosis, possibly by increasing portal pressure. Whether weight reduction can be safely achieved through lifestyle (LS) changes (diet and exercise) in overweight/obese patients with cirrhosis, and if weight loss reduces portal pressure in this setting, is unknown. This prospective, multicentric, uncontrolled pilot study enrolled patients with compensated cirrhosis, portal hypertension (hepatic venous pressure gradient [HVPG] ≥6 mm Hg), and body mass index (BMI) ≥26 kg/m2 in an intensive 16-week LS intervention program (personalized hypocaloric normoproteic diet and 60 min/wk of supervised physical activity). We measured HVPG, body weight (BW) and composition, adipokines, health-related quality of life, and safety data before and after the intervention. Changes in HVPG and BW were predefined as clinically relevant if ≥10% and ≥5%, respectively. Safety and BW were reassessed after 6 months. 60 patients were included and 50 completed the study (56 ± 8 years old; 62% male; nonalcoholic steatohepatitis etiology 24%; BMI 33.3 ± 3.2 kg/m2 ; Child A 92%; HVPG ≥10 mm Hg, 72%). LS intervention significantly decreased BW (average, -5.0 ± 4.0 kg; P < 0.0001), by ≥5% in 52% and ≥10% in 16%. HVPG also significantly decreased (from 13.9 ± 5.6 to 12.3 ± 5.2 mm Hg; P < 0.0001), by ≥10% in 42% and ≥20% in 24%. A ≥10% BW loss was associated with a greater decrease in HVPG (-23.7 ± 19.9% vs. -8.2 ± 16.6%; P = 0.024). No episodes of clinical decompensation occurred. Weight loss achieved at 16 weeks was maintained at 6 months; Child and Model for End-Stage Liver Disease scores did not change. CONCLUSION: Sixteen weeks of diet and moderate exercise were safe and reduced BW and portal pressure in overweight/obese patients with cirrhosis and portal hypertension. (Hepatology 2017;65:1293-1305).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology. 2017. PMID: 27997989. doi:10.1002/hep.28992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。